NCT02176083 is a NA clinical trial of Text message management prompts in Breast Cancer, sponsored by University of California, San Diego.

Who is sponsoring NCT02176083?

NCT02176083 is sponsored by University of California, San Diego.

What drugs are being tested in NCT02176083?

Interventions in NCT02176083: Text message management prompts.

What condition does NCT02176083 study?

NCT02176083 studies Breast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms.

Is NCT02176083 still recruiting?

NCT02176083 is currently completed. Last updated 20 April 2020.

Are results published for NCT02176083?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-04-20 · How we verify

NCT02176083

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reproductive Health Survivorship Care Plan Pilot

Completed NA Results posted Last updated 20 April 2020

What this trial tests

NA trial testing Text message management prompts in Breast Cancer in 38 participants. Completed in 31 December 2015.

Timeline

20 March 2014

Primary endpoint
31 August 2014

31 December 2015

Quick facts

Lead sponsor	University of California, San Diego
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	38
Start date	20 March 2014
Primary completion	31 August 2014
Estimated completion	31 December 2015
Sites	2 locations across United States

Drugs / interventions tested

Text message management prompts

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Hot Flashes — all drugs for Hot Flashes →
Vaginal Dryness — all drugs for Vaginal Dryness →
Estrogen Deprivation Symptoms — all drugs for Estrogen Deprivation Symptoms →

Sponsor

University of California, San Diego

Who can join

Adults 18 to 45, female only, with Breast Cancer or Hot Flashes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Hot Flash Frequency Primary · 1 week

Median number of daily hot flashes over 4th week of study

Group	Value	95% CI
Intervention	2.2	1.2 – 3.6
Control	1.4	0.7 – 2.3

Sponsor's own description

Most young breast cancer patients undergo chemotherapy and/or endocrine therapy, treatments that impair ovarian function and result in significant reproductive health late effects. These late effects include symptoms of estrogen deprivation (e.g., hot flashes and vaginal dryness), which are distressing in young breast cancer survivors (YBCS). The goal of this pilot study is to test the feasibility of a 4-week text message based intervention on hot flashes and vaginal dryness in YBCS. YBCS will be randomized in a 1:1 ratio to the intervention (text messages on hot flash and vaginal dryness management) and control arms. All participants will be prompted to provide daily hot flash frequency and severity via text messaging. The primary hypothesis is YBCS will have high rates of daily hot flash reporting via text messaging. Secondarily, we will compare changes in hot flash frequency, hot flash severity and vagina dryness between the intervention and control arms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of California, San Diego trials

Trials by the same sponsor.

NCT07342543 — Guided Physical Activity Counseling for Hypertension in Primary Care · NA · not yet recruiting
NCT06505317 — Artificial Intelligence for Early Detection of Peripheral Artery Disease · NA · not yet recruiting
NCT07211802 — CKM For Safe Use of SGLT2i in Type 1 Diabetes · Phase 3 · not yet recruiting
NCT07524751 — Culturally Adapted Pain Management for Indigenous Peoples · NA · not yet recruiting
NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02176083 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 20 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02176083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing